Evidence map›Paper›PMID 23584602›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2013

Valproic acid: an anticonvulsant drug with potent antinociceptive and anti-inflammatory properties.

José Christian Machado Ximenes, Danilo de Oliveira Gonçalves, Rafaelly Maria Pinheiro Siqueira, Kelly Rose Tavares Neves, Gilberto Santos Cerqueira, Alyne Oliveira Correia, Francisco Hélder Cavalcante Félix, Luzia Kalyne Almeida Moreira Leal, Gerly Anne de Castro Brito, Maria da Graça Naffah-Mazzacorati and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 1 pooled it
12.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 1 synthesis or guideline pooled it, 73 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

José Christian Machado XimenesFederal University of São Paulo, São Paulo, São Paulo, Brazil.
Danilo de Oliveira Gonçalves
Rafaelly Maria Pinheiro Siqueira
Kelly Rose Tavares Neves
Gilberto Santos Cerqueira
Alyne Oliveira Correia
Francisco Hélder Cavalcante Félix
Luzia Kalyne Almeida Moreira Leal
Gerly Anne de Castro Brito
Maria da Graça Naffah-Mazzacorati
Glauce Socorro de Barros Viana
Universidade Federal do Ceará · BRUniversidade Federal de São Paulo · BRCentro Universitário do Norte · BRSabin Vaccine Institute · USUniversidade de Fortaleza · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Valproic acid (VA) is a major antiepileptic drug, used for several therapeutic indications. It has a wide activity spectrum, reflecting on mechanisms of action that are not fully understood. The objectives of this work were to study the effects of VA on acute models of nociception and inflammation in rodents. VA (0.5, 1, 10, 25, and 50 mg/kg, p.o.) effects were evaluated on the carrageenan-induced paw edema, carrageenan-induced peritonitis, and plantar tests in rats, as well as by the formalin test in mice. The HE staining and immunohistochemistry assay for TNF-α in carrageenan-induced edema, from paws of untreated and VA-treated rats, were also carried out. VA decreased paw edema after carrageenan, and maximum effects were seen with doses equal to or higher than 10 mg/kg. VA also preserved the tissue architecture as assessed by the HE staining. Immunohistochemical studies revealed that VA significantly reduced TNF-α immunostaining in carrageenan-inflamed rat paws. In addition, the anti-inflammatory action of VA was potentiated by pentoxifylline (a phosphodiesterase inhibitor, known to inhibit TNF-α production), but not by sodium butyrate or by suberoylanilide hydroxamic acid (SAHA), nonspecific and specific inhibitors, respectively, of histone deacetylase. However, the decrease in the number of positive TNF-α cells in the rat paw was drastically potentiated in the VA + SAHA associated group. VA also reduced leukocytes and myeloperoxidase (MPO) releases to the peritoneal exudate, in the carrageenan-induced peritonitis. Although in the formalin test, VA inhibited both phases, the inhibition was mainly on the second phase. Furthermore, VA significantly increased the reaction time to thermal stimuli, as assessed by the plantar test. VA is a multi-target drug, presenting potent antinociceptive and anti-inflammatory properties at a lower dose range. These effects are partly dependent upon its inhibitory action on TNF-α-related pathways. However, the participation of the HDAC inhibition with the VA anti-inflammatory action cannot be ruled out. Inflammatory processes are associated with free radical damage and oxidative stress, and their blockade by VA could also explain the present results.

Indexed as

AnalgesicsAnimalsAnticonvulsantsAnti-Inflammatory AgentsButyric AcidCarrageenanDrug SynergismEdemaFootFormaldehydeHot TemperatureHydroxamic AcidsLeukocyte CountMaleMicePainAnalgesicsAnticonvulsantsAnti-Inflammatory AgentsButyric AcidCarrageenanFormaldehydeHydroxamic AcidsPentoxifyllinePeroxidaseTumor Necrosis Factor-alphaValproic AcidVorinostat

Identifiers

PMID23584602
OpenAlexW2003429977

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.